Edgestream Partners L.P. Purchases 40,369 Shares of Insmed Incorporated (NASDAQ:INSM)

Edgestream Partners L.P. grew its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 1,242.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 43,619 shares of the biopharmaceutical company's stock after buying an additional 40,369 shares during the period. Edgestream Partners L.P.'s holdings in Insmed were worth $3,011,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC raised its holdings in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 163 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 248 shares in the last quarter. Spire Wealth Management purchased a new position in shares of Insmed in the fourth quarter worth $47,000. Smartleaf Asset Management LLC lifted its holdings in shares of Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Insmed during the fourth quarter valued at $86,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on INSM shares. Wells Fargo & Company boosted their target price on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 19th. Stifel Nicolaus lowered their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. JPMorgan Chase & Co. raised their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Guggenheim reiterated a "buy" rating and set a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th. Finally, UBS Group lifted their price objective on Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

Remove Ads

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $77.79, for a total value of $1,458,562.50. Following the completion of the transaction, the chief executive officer now directly owns 334,186 shares of the company's stock, valued at approximately $25,996,328.94. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 3,470 shares of the company's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00. Following the sale, the chief financial officer now directly owns 114,736 shares in the company, valued at approximately $7,538,155.20. The trade was a 2.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 550,957 shares of company stock worth $42,859,028 in the last quarter. 4.60% of the stock is owned by corporate insiders.

Insmed Price Performance

Shares of INSM stock traded up $1.03 on Thursday, hitting $75.07. 1,183,047 shares of the stock traded hands, compared to its average volume of 1,954,951. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The firm has a 50 day simple moving average of $75.93 and a two-hundred day simple moving average of $73.71. The firm has a market cap of $13.59 billion, a price-to-earnings ratio of -13.43 and a beta of 1.28.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million during the quarter, compared to analysts' expectations of $102.31 million. As a group, equities research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.